Stefanie Bette1, Jens Gempt2, Thomas Huber3, Tobias Boeckh-Behrens3, Florian Ringel2, Bernhard Meyer2, Claus Zimmer3, Jan S Kirschke3. 1. Department of Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. Electronic address: stefanie.bette@tum.de. 2. Department of Neurosurgery, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. 3. Department of Neuroradiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Abstract
OBJECTIVE: Postoperative magnetic resonance imaging (MRI) is recommended soon after glioma surgery to avoid reactive nonneoplastic contrast enhancement indistinguishable from tumor. The purpose of this study was to analyze these patterns of postoperative contrast enhancement at 3 T to define the optimal time frame for postoperative MRI. METHODS: MRI for 206 glioblastoma surgeries in 173 patients who underwent pre- and postoperative and at least 1 follow-up 3T MRI for each surgery were analyzed retrospectively. Postoperative MRI was assessed in consensus by 2 neuroradiologists, blinded to the time after surgery. Postoperative contrast enhancement marginal to the resection cavity was analyzed and classified as vascular, linear, or nodular. The cause of the contrast enhancement (ie, reactive vs. tumor) was assessed by comparing pre-, postoperative, and follow-up MRI. RESULTS: Within 45 hours after surgery, reactive enhancement appeared in 17.9% of cases. After 45 hours, the fraction of reactive changes increased to 34.1%. Linear enhancement was more often reactive (66.1%, 39/59 cases), whereas nodular enhancement was mainly residual tumor (93.2%, 68/73 cases). Specificity of nodular enhancement was high for tumor recurrence/tumor progression (91.5%). CONCLUSIONS: To avoid an increasing number of MRIs with reactive contrast enhancement, postoperative MRI at 3 T should be performed within 45 hours after surgery. However, reactive contrast enhancement can occur at all time points. In these cases, the pattern of the contrast enhancement may help to differentiate its cause.
OBJECTIVE: Postoperative magnetic resonance imaging (MRI) is recommended soon after glioma surgery to avoid reactive nonneoplastic contrast enhancement indistinguishable from tumor. The purpose of this study was to analyze these patterns of postoperative contrast enhancement at 3 T to define the optimal time frame for postoperative MRI. METHODS: MRI for 206 glioblastoma surgeries in 173 patients who underwent pre- and postoperative and at least 1 follow-up 3T MRI for each surgery were analyzed retrospectively. Postoperative MRI was assessed in consensus by 2 neuroradiologists, blinded to the time after surgery. Postoperative contrast enhancement marginal to the resection cavity was analyzed and classified as vascular, linear, or nodular. The cause of the contrast enhancement (ie, reactive vs. tumor) was assessed by comparing pre-, postoperative, and follow-up MRI. RESULTS: Within 45 hours after surgery, reactive enhancement appeared in 17.9% of cases. After 45 hours, the fraction of reactive changes increased to 34.1%. Linear enhancement was more often reactive (66.1%, 39/59 cases), whereas nodular enhancement was mainly residual tumor (93.2%, 68/73 cases). Specificity of nodular enhancement was high for tumor recurrence/tumor progression (91.5%). CONCLUSIONS: To avoid an increasing number of MRIs with reactive contrast enhancement, postoperative MRI at 3 T should be performed within 45 hours after surgery. However, reactive contrast enhancement can occur at all time points. In these cases, the pattern of the contrast enhancement may help to differentiate its cause.
Authors: Shivaram Avula; Andrew Peet; Giovanni Morana; Paul Morgan; Monika Warmuth-Metz; Tim Jaspan Journal: Childs Nerv Syst Date: 2021-05-10 Impact factor: 1.475
Authors: A Jhaveri; A Amirabadi; P Dirks; A V Kulkarni; M M Shroff; N Shkumat; T Krings; V M Pereira; V Rea; P Muthusami Journal: AJNR Am J Neuroradiol Date: 2019-06-27 Impact factor: 3.825
Authors: Raymond Y Huang; Wenya Linda Bi; Brent Griffith; Timothy J Kaufmann; Christian la Fougère; Nils Ole Schmidt; Jöerg C Tonn; Michael A Vogelbaum; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Ian F Dunn Journal: Neuro Oncol Date: 2019-01-14 Impact factor: 12.300
Authors: Thomas Huber; Georgina Alber; Stefanie Bette; Johannes Kaesmacher; Tobias Boeckh-Behrens; Jens Gempt; Florian Ringel; Hanno M Specht; Bernhard Meyer; Claus Zimmer; Benedikt Wiestler; Jan S Kirschke Journal: PLoS One Date: 2017-02-28 Impact factor: 3.240
Authors: Michael Weller; Martin van den Bent; Matthias Preusser; Emilie Le Rhun; Jörg C Tonn; Giuseppe Minniti; Martin Bendszus; Carmen Balana; Olivier Chinot; Linda Dirven; Pim French; Monika E Hegi; Asgeir S Jakola; Michael Platten; Patrick Roth; Roberta Rudà; Susan Short; Marion Smits; Martin J B Taphoorn; Andreas von Deimling; Manfred Westphal; Riccardo Soffietti; Guido Reifenberger; Wolfgang Wick Journal: Nat Rev Clin Oncol Date: 2020-12-08 Impact factor: 66.675
Authors: Fatih Incekara; Marion Smits; Linda Dirven; Eelke M Bos; Rutger K Balvers; Iain K Haitsma; Joost W Schouten; Arnaud J P E Vincent Journal: Front Oncol Date: 2021-05-19 Impact factor: 6.244